|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,145.00 JPY | -0.09% |
|
-0.02% | +2.48% |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| 06-24 | Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer | MT |
| Market Cap | 3,843B 23.74B 20.86B 19.24B 18B 33.69B 2,240B 34.45B 229B 89.19B 1,108B 89.2B 87.24B | P/E 2027 * |
11.1x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,766B 23.27B 20.45B 18.86B 17.64B 33.02B 2,195B 33.77B 225B 87.41B 1,086B 87.41B 85.49B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.66x |
| Free-Float |
98.88% | Yield 2027 * |
3.75% | Yield 2028 * | 3.87% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.09% | ||
| 1 week | -0.02% | ||
| Current month | -6.04% | ||
| 1 month | +0.52% | ||
| 3 months | -17.80% | ||
| 6 months | +2.19% | ||
| Current year | +2.48% |
| 1 week | 2,122 |  | 2,181 |
| 1 month | 2,041 | | 2,283 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | -0.02% | +53.00% | -0.81% | 23.77B | |
| +7.13% | +9.97% | +55.80% | +163.38% | 1,077B | |
| +3.99% | +11.50% | +67.09% | +56.27% | 613B | |
| +4.20% | +17.03% | +38.97% | +91.19% | 448B | |
| +0.99% | +4.85% | +28.17% | +22.04% | 332B | |
| +1.82% | +8.19% | +40.04% | +27.95% | 293B | |
| +0.22% | +6.75% | +31.30% | +42.64% | 286B | |
| +0.73% | +8.53% | -27.33% | -39.55% | 215B | |
| +1.56% | +6.14% | +29.30% | +61.91% | 193B | |
| +3.26% | +3.33% | +15.55% | +67.87% | 159B | |
| Average | +2.38% | +7.20% | +33.19% | +49.29% | 363.98B | |
| Weighted average by Cap. | +3.82% | +8.87% | +41.83% | +80.57% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,249B 13.89B 12.21B 11.26B 10.54B 19.72B 1,311B 20.17B 134B 52.2B 648B 52.21B 51.06B | 2,079B 12.85B 11.29B 10.41B 9.74B 18.23B 1,212B 18.64B 124B 48.26B 599B 48.27B 47.21B |
| Net income | 346B 2.14B 1.88B 1.73B 1.62B 3.03B 202B 3.1B 20.63B 8.03B 99.68B 8.03B 7.85B | 327B 2.02B 1.78B 1.64B 1.53B 2.87B 191B 2.93B 19.53B 7.6B 94.34B 7.6B 7.43B |
| Net Debt | -76.82B -475M -417M -385M -360M -673M -44.78B -689M -4.58B -1.78B -22.14B -1.78B -1.74B | -391B -2.42B -2.12B -1.96B -1.83B -3.43B -228B -3.51B -23.34B -9.08B -113B -9.08B -8.88B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | ¥2,145.00 | -0.09% | 6,216,800 |
| 25/06/26 | ¥2,147.00 | -0.58% | 4,672,000 |
| 24/06/26 | ¥2,159.50 | +1.24% | 5,998,200 |
| 23/06/26 | ¥2,133.00 | -2.02% | 6,256,400 |
| 22/06/26 | ¥2,177.00 | +1.47% | 5,402,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
